FindTrial
Sign In

Crizanlizumab

DRUG14 trials

Sponsors

Novartis Pharmaceuticals, Johns Hopkins University, Washington University School of Medicine, Andria Ford, Children's Hospital Los Angeles

Conditions

COVID-19MyelofibrosisPriapismRVCL - Retinal Vasculopathy Cerebral LeukoencephalopathySickle Cell DiseaseSickle Cell Disease (SCD)

Phase 1

Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients
TerminatedNCT04097821
Novartis PharmaceuticalsMyelofibrosis
Start: 2019-09-26End: 2024-08-28Updated: 2025-08-07
Crizanlizumab Improves Tissue Oxygen Supply Demand Matching in Patients With Sickle Cell Anemia
Not yet recruitingNCT05469828
Children's Hospital Los AngelesSickle Cell Disease
Start: 2024-07-01End: 2029-07-01Target: 30Updated: 2023-08-30

Phase 2

Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC)
CompletedNCT03264989
Novartis PharmaceuticalsSickle Cell Disease (SCD)
Start: 2017-12-19End: 2023-06-26Updated: 2024-10-09
Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients
CompletedNCT03474965
Novartis PharmaceuticalsSickle Cell Disease (SCD)
Start: 2018-10-01End: 2024-11-06Updated: 2025-10-16
A Study to Evaluate the Safety and Efficacy of Crizanlizumab in Sickle Cell Disease Related Priapism
CompletedNCT03938454
Novartis PharmaceuticalsPriapism
Start: 2019-10-16End: 2023-11-29Updated: 2026-01-13
Crizanlizumab for Treating COVID-19 Vasculopathy
CompletedNCT04435184
Johns Hopkins UniversityCOVID-19
Start: 2020-07-09End: 2021-01-04Updated: 2021-11-09
Crizanlizumab for Treatment of Retinal Vasculopathy With Cerebral Leukoencephalopathy (RVCL)
Active, not recruitingNCT04611880
Washington University School of MedicineRVCL - Retinal Vasculopathy Cerebral Leukoencephalopathy
Start: 2021-01-25End: 2025-12-31Target: 20Updated: 2025-06-26

Phase 3

A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
RecruitingNCT06439082
Novartis PharmaceuticalsSickle Cell Disease
Start: 2024-10-24End: 2030-04-19Target: 315Updated: 2026-03-27

Phase 4

Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
RecruitingNCT04657822
Novartis PharmaceuticalsSickle Cell Disease
Start: 2021-06-10End: 2031-06-10Target: 130Updated: 2025-10-27
An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab in Sickle Cell Disease Patients
CompletedNCT04662931
Novartis PharmaceuticalsSickle Cell Disease (SCD)
Start: 2021-07-14End: 2024-02-14Updated: 2025-09-26

Unknown Phase

MAP to Provide Access to Crizanlizumab, for Sickle Cell Disease Patients
NCT03720626
Novartis PharmaceuticalsSickle Cell Disease
Updated: 2025-12-05
Prospective, Observational Study in Sickle Cell Disease Patients on Crizanlizumab Treatment in Middle East Countries and India
TerminatedNCT05020873
Novartis PharmaceuticalsSickle Cell Disease
Start: 2021-11-04End: 2023-08-31Updated: 2024-06-24
Study of Crizanlizumab for Prevention of Silent Cerebral Infarcts in SCA
NCT05334576
Andria FordSickle Cell Disease
Start: 2022-08-01End: 2025-07-01Target: 31Updated: 2023-03-06
Characteristics of Patients With Sickle Cell Disease
CompletedNCT05494541
Novartis PharmaceuticalsSickle Cell Disease
Start: 2021-08-30End: 2021-10-27Updated: 2022-11-08

Related Papers

A phase III, multicenter, randomized, placebo controlled, double-blind study to assess efficacy and safety of crizanlizumab (5 mg/kg) versus placebo, with or without hydroxyurea/hydroxycarbamide therapy, in adolescent and adult sickle cell disease patients with frequent vaso-occlusive crises: The sparkle study
Blood2025-11-03
ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis
Blood Advances2025-05-07
Safety profile of crizanlizumab 5.0 mg/kg in sickle cell disease: pooled data from clinical trials
Journal of sickle cell disease.2025-01-01
Pharmacokinetics/Pharmacodynamics, Safety, and Efficacy of Crizanlizumab in Patients with Sickle Cell Disease Aged 6 to <12 Years: 2-Year Data from the Phase 2 Solace-Kids Study
Blood2024-11-051 citations
Pharmacokinetics, pharmacodynamics, safety, and efficacy of crizanlizumab in patients with sickle cell disease: final results from the phase II SOLACE-adults study.
2024-11-033 citations
Real‐World Evidence of Crizanlizumab Showing Reductions in Vaso‐Occlusive Crises and Opioid Usage in Sickle Cell Disease
European Journal Of Haematology2024-10-292 citations
Crizanlizumab for retinal vasculopathy with cerebral leukoencephalopathy in a phase II clinical study
Journal of Clinical Investigation2024-05-076 citations
Primary Analysis of Spartan: A Phase 2 Trial to Assess the Efficacy and Safety of Crizanlizumab in Patients with Sickle Cell Disease Related Priapism
Blood2023-11-0217 citations
Safety Profile of Crizanlizumab 5.0 Mg/Kg in Sickle Cell Disease: Pooled Data from Clinical Trials
Blood2023-11-021 citations
Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of Crizanlizumab in Patients with Sickle Cell Disease: Final Interim Analysis Results from the Phase 2 Solace-Adults Study
Blood2023-11-02
S268: INTERIM ANALYSIS OF A PHASE 2 TRIAL TO ASSESS THE EFFICACY AND SAFETY OF CRIZANLIZUMAB IN SICKLE CELL DISEASE PATIENTS WITH PRIAPISM (SPARTAN)
HemaSphere2023-08-013 citations
S267: PHARMACOKINETICS/PHARMACODYNAMICS, SAFETY AND EFFICACY OF CRIZANLIZUMAB IN PATIENTS WITH SICKLE CELL DISEASE AGED 12 TO <18 YEARS: 2-YEAR DATA FROM THE PHASE 2 SOLACE-KIDS STUDY
HemaSphere2023-08-011 citations
Population Pharmacokinetics and Pharmacodynamics of Crizanlizumab in Healthy Subjects and Patients with Sickle Cell Disease.
2022-12-181 citations
Epidemiology and treatment of priapism in sickle cell disease.
2022-12-0122 citations
Interim Analysis of a Phase 2 Trial to Assess the Efficacy and Safety of Crizanlizumab in Sickle Cell Disease Patients with Priapism (SPARTAN)
Blood2022-11-157 citations
Siremadlin, a Human Double Minute-2 (HDM2) Inhibitor, Added to Ruxolitinib after Suboptimal Response to Ruxolitinib Alone in Patients with Myelofibrosis: Results from Part 1 of the Phase 1/2 Adore Study
Blood2022-11-154 citations
Pharmacokinetics, pharmacodynamics, safety, and efficacy of crizanlizumab in patients with sickle cell disease
Blood Advances2022-11-1022 citations
O-04: INCIDENCE OF VASO-OCCLUSIVE CRISES IN PATIENTS WITH SICKLE CELL DISEASE (SCD) AND A HIGH BASELINE DISEASE BURDEN TREATED WITH CRIZANLIZUMAB IN A REAL-WORLD SETTING: RESULTS FROM A MANAGED ACCESS PROGRAM (MAP)
HemaSphere2022-08-01
P1491: REAL-WORLD INCIDENCE OF VASO-OCCLUSIVE CRISES IN PATIENTS WITH SICKLE CELL DISEASE (SCD) AND A HIGH BASELINE DISEASE BURDEN TREATED WITH CRIZANLIZUMAB: RESULTS FROM A MANAGED ACCESS PROGRAM (MAP)
HemaSphere2022-06-011 citations
S122: SAFETY AND EFFICACY OF CRIZANLIZUMAB IN ADOLESCENTS WITH SICKLE CELL DISEASE (SCD): INITIAL DATA FROM THE PHASE II, MULTICENTER, OPEN-LABEL SOLACE-KIDS TRIAL
HemaSphere2022-01-013 citations

10 more papers not shown